Skip to main content
PMC home page
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
. 2007 May 1;5(2):125–131. doi: 10.1111/j.1582-4934.2001.tb00145.x

Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure

A M Katz 1,✉
PMCID: PMC6517809  PMID: 12067495

The content is available as a PDF (107.4 KB).

References

  • 1. Withering W., An account of the foxglove and some of its medical uses, Birmingham, Swinney, 1785.
  • 2. Jarcho S., The concept of heart failure. From Avicenna to Albertini, Cambridge MA , Harvard Univ. Press, 1980. [Google Scholar]
  • 3. Katz A.M., Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle. Part I. Heart failure as a disorder of the cardiac pump, J. Cardiac Failure, 3:319–334, 1997. [DOI] [PubMed] [Google Scholar]
  • 4. Katz A.M., Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle. Part II. Hypertrophy and dilatation of the failing heart, J. Cardiac Failure, 4:67–81, 1998. [DOI] [PubMed] [Google Scholar]
  • 5. Katz A.M., Heart failure: pathophysiology, molecular biology, and clinical management. Philadelphia , Lippincott/Williams & Wilkins, 2000. [Google Scholar]
  • 6. Harris P., Evolution and the cardiac patient, Cardiovasc. Res., 17:313–319, 373–378, 437–445, 1983. [DOI] [PubMed] [Google Scholar]
  • 7. Francis G.S., Goldsmith S.R., Levine T.B., Olivari M.T., Cohn J.N., The neurohumoral axis in congestive heart failure, Ann. Int. Med., 101:370–377, 1984. [DOI] [PubMed] [Google Scholar]
  • 8. Morgagni J.B., The seats and causes of diseases. Book II. On diseases of the thorax. Letter XVII, Article 13. Tr. Alexander B. London , Millar and Cadell, 1769. [Google Scholar]
  • 9. Katz A.M., Tonic and phasic mechanisms in the regulation of myocardial contractility. Basic Res. Cardiol., 71:447–455, 1976. [DOI] [PubMed] [Google Scholar]
  • 10. Burton A.C., Physical principles of circulatory phenomena: The physical equilibria of the heart and blood vessels In: Handbook of Physiology, Section 2: Circulation, Vol. 1 Ed: Hamilton WF, Dow P., Am. Physiol. Soc., Washington , DC , pp. 85–106, 1962. [Google Scholar]
  • 11. Sandler H., Dodge H.T., Left ventricular tension and stress in man, Circ. Res., 13:91–104, 1963. [DOI] [PubMed] [Google Scholar]
  • 12. Hood W.P. Jr., Rackley C.E., Rolett E.L., Wall stress in the normal and hypertrophied human left ventricle, Am. J. Cardiol., 22:5550–558, 1968. [DOI] [PubMed] [Google Scholar]
  • 13. Grossman W., Jones D., McLaurin L.P., Wall stress and patterns of hypertrophy in the human left ventricle, J. Clin. Invest., 56:56–64, 1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Meerson F.Z., On the mechanism of compensatory hyperfunction and insufficiency of the heart, Cor et Vasa, 3:161–177, 1961. [PubMed] [Google Scholar]
  • 15. Alpert N.R., Gordon M.S., Myofibrillar adenosine triphosphatase activity in congestive heart failure, Am. J. Physiol., 202:940–946, 1962. [DOI] [PubMed] [Google Scholar]
  • 16. Katz A.M., Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure, New Eng. J. Med., 322:100–110, 1990. [DOI] [PubMed] [Google Scholar]
  • 17. Bourne H.R., Team blue sees red, Nature, 376:727–729, 1995. [DOI] [PubMed] [Google Scholar]
  • 18. van Biesen T., Luttrell L.M., Hawes B.E., Lefkowitz R.J., Mitogenic signaling via G proteincoupled receptors, Endoc. Rev., 17:698–714, 1996. [DOI] [PubMed] [Google Scholar]
  • 19. Packer M., Cohn J.N., Consensus recommendations for the management of heart failure, Am. J. Cardiol. 83(Suppl 2a):1A–38A, 1999. [PubMed] [Google Scholar]
  • 20. Katz A.M., Angiotensin II: Hemodynamic regulator or growth factor?, J. Mol. Cell. Cardiol., 22:739–747, 1990. [DOI] [PubMed] [Google Scholar]
  • 21. Katz A.M., The cardiomyopathy of overload: An unnatural growth response in the hypertrophied heart, Ann. Int. Med., 121:363–371, 1994. [DOI] [PubMed] [Google Scholar]
  • 22. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H., for the US Carvedilol Heart Failure Study Group, New Eng. J. Med., 334:1349–1355, 1996. [DOI] [PubMed] [Google Scholar]
  • 23. LeChat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.‐P., Clinical effects of β‐adrenergic blockade in chronic heart failure, Circulation, 98:1184–1191, 1998. [DOI] [PubMed] [Google Scholar]
  • 24. CIBIS‐II Investigators and Committees , The cardiac insufficiency bisoprolol study II (CIBISII): A randomised trial, Lancet, 353:9–13, 1999. [PubMed] [Google Scholar]
  • 25. Merit‐HF Study Group , Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT‐HF), Lancet, 353:2001–2007, 1999. [PubMed] [Google Scholar]
  • 26. Eichhorn E.J., Bristow M.R., Medical therapy can improve the biological properties of the chronically failing heart, Circulation, 94:2285–2296, 1996. [DOI] [PubMed] [Google Scholar]
  • 27. Mann D.L., Mechanisms and models in heart failure: A combinatorial approach, Circulation, 100:999–1008, 1999. [DOI] [PubMed] [Google Scholar]
  • 28. Chien K.R., Stress pathways and heart failure, Cell, 98:555–558, 1999. [DOI] [PubMed] [Google Scholar]
  • 29. Packer M., Carver J.R., Rodeheffer R.J.. Ivanhoe R.J., DiBianco R., Zeldis S.M., Hendrix G.H., Bommer W.J., Elkayam U., Kukin M.L., Mallis G.I., Sollano J.A., Shannon J., Tandon P.K., DeMets D.L., Effect of oral milrinone on mortality in severe heart failure, New Eng. J. Med., 325:1468–1475, 1991. [DOI] [PubMed] [Google Scholar]
  • 30. Cohn J.N., Goldstein S.O., Greenberg B.H., Lorell B.H., Bourge R.C., Jaski B.E., Gottlieb S.O., McGrew F., Demets D.L., White B.G., A dose‐dependent increase in mortality with vesnarinone among patients with severe heart failure, N. Engl. J. Med., 339:1810–1816, 1998. [DOI] [PubMed] [Google Scholar]
  • 31. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, New Eng. J. Med., 341:709–717, 1999. [DOI] [PubMed] [Google Scholar]
  • 32. Bénitah J.‐P., Vassort G., Aldosterone upregulated Ca2+ current in adult rat cardiomyocytes, Circ. Res., 95: 1139–1145, 1999. [DOI] [PubMed] [Google Scholar]
  • 33. Zannad F., Alla F., Douset B., Perez A., Pitt B., on behalf of the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES), Circulation, 102:2700–2706, 2000. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES